SLNSilence Therapeutics plc
Earnings
When Silence Therapeutics plc reports, what it reported each quarter, and how the stock took the results.
11 quarters. Mar 31, 2024 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 4, before the open
Thu, Mar 4, 2027in 106 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 22 – Mar 12
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $34.00K
- Revenue, change from a year earlier: Q3 2026 −100.0%, Q2 2026 −100.0%, Q1 2026 +197.2%, Q4 2025 −99.9%
- Net income
- -$11.77M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $0.00
- −100.0%
- Net income
- -$12.43M
- N/M
- EPS
- -$0.08
- N/M
- Revenue
- $0.00
- −100.0%
- Net income
- -$12.27M
- N/M
- EPS
- -$0.09
- N/M
- Revenue
- $422.00K
- +197.2%
- Net income
- -$14.96M
- N/M
- EPS
- -$0.11
- N/M
- Revenue
- $34.00K
- −99.9%
- Net income
- -$11.77M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 12, 2026 · pre-market | Nov 13, 2026 | 44 d | 10-Q | $0.00 | −100.0% | -$0.08 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 10, 2026 · pre-market | Aug 10, 2026 | 41 d | 10-Q | $0.00 | −100.0% | -$0.09 | +29.3% | |
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · pre-market | May 7, 2026 | 37 d | 10-Q | $422.00K | +197.2% | -$0.11 | 5.6% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 5, 2026 · pre-market | Mar 5, 2026 | 64 d | 10-K | $34.00K | −99.9% | — | 4.6% | |
| Q3 2025 | Sep 30, 2025 | Nov 6, 2025 · pre-market | Nov 6, 2025 | 37 d | 10-Q | $159.00K | −89.4% | -$0.15 | +3.4% | |
| Q2 2025 | Jun 30, 2025 | Aug 7, 2025 · pre-market | Aug 7, 2025 | 38 d | 10-Q | $224.00K | −70.4% | -$0.19 | 0.2% | |
| Q1 2025 | Mar 31, 2025 | May 8, 2025 · pre-market | May 8, 2025 | 38 d | 10-Q | $142.00K | −99.1% | -$0.20 | 3.8% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Feb 27, 2025 · after-hours | Feb 27, 2025 | 58 d | 10-K | $25.31M | — | — | 5.2% | |
| Q3 2024 | Sep 30, 2024 | — | — | — | — | $1.50M | — | -$0.25 | — | |
| Q2 2024 | Jun 30, 2024 | — | — | — | — | $756.00K | — | -$0.14 | — | |
| Q1 2024 | Mar 31, 2024 | — | — | — | — | $15.70M | — | -$0.02 | — | |
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Silence Therapeutics plc · CIK 1479615 · Engraved from SEC EDGAR